Bundibugyo Virus: No Approved Vaccines or Treatments

The World Health Organization has raised its highest level of concern due to the current Ebola outbreak, primarily involving the Bundibugyo virus. Critically, there are neither approved vaccines nor specific treatments for this circulating strain. While three main Ebola vaccines exist, they target a different strain (EBOV) and are not directly applicable. Vaccines against Bundibugyo are still in the pre-clinical stage, meaning they have not undergone human testing, and no stockpiles are ready for deployment.

Experts suggest that antibodies from Ebola virus (EBOV) vaccines might offer some limited protection against Bundibugyo due to their close relationship. However, the extent of this protection is unknown, and deploying such vaccines without clear efficacy data could undermine public trust. The lack of preparedness is attributed to past failures in prioritizing the development and stockpiling of vaccines against all dangerous Ebola strains.

Treatment for Ebola, in general, relies on supportive care, including managing fluid balance, shock, bleeding, and co-infections, as no specific approved treatments exist for Bundibugyo. Social factors such as poverty, refugee flows, and poor living conditions significantly contribute to the ease with which the pathogen spreads. Pharmaceutical companies have shown limited commercial interest in developing countermeasures for this virus in Africa, a disparity highlighted when compared to potential market interest in Western countries.